advertisement

---

1 General aspects (0)   1.1 Epidemiology (11)   1.2 Population genetics (2)   1.3 Pathogenesis (4)   1.4 Quality of life (8)   1.5 Glaucomas as cause of blindness (7)   1.6 Prevention and screening (4) 2 Anatomical structures in glaucoma (0)   2.1 Conjunctiva (0)   2.2 Cornea (23)   2.3 Sclera (3)   2.4 Anterior chamber angle (5)   2.5 Meshwork (0)     2.5.1 Trabecular meshwork (10)     2.5.2 Schlemms canal (0)     2.5.3 Scleral outlet channels (0)   2.6 Aqueous humor dynamics (0)     2.6.1 Production (0)     2.6.2 Outflow (1)       2.6.2.1 Trabecular meshwork (1)       2.6.2.2 Uveoscleral (0)     2.6.3 Compostion (3)   2.7 Episcleral veins and venous pressure (0)   2.8 Iris (2)   2.9 Ciliary body (1)   2.10 Lens (0)   2.11 Vitreous body (0)   2.12 Choroid, peripapillary choroid, peripapillary atrophy (2)   2.13 Retina and retinal nerve fibre layer (21)   2.14 Optic disc (14)   2.15 Optic nerve (2)   2.16 Chiasma and retrochiasmal central nervous system (1)   2.17 Stem cells (1)   2.20 Other (0) 3 Laboratory methods (0)   3.1 Microscopy (6)   3.2 Electron microscopy (0)   3.3 Immunohistochemistry (6)   3.4 Molecular genetics (0)     3.4.1 Linkage studies (0)     3.4.2 Gene studies (12)   3.5 Molecular biology incl. SiRNA (13)   3.6 Cellular biology (15)   3.7 Biochemistry (2)   3.8 Pharmacology (2)   3.9 Pathophysiology (5)   3.10 Immunobiology (5)   3.11 Pharmacogenetics (0)   3.12 Proteomics (1)   3.13 In vivo imaging (0)     3.13.1 Laser Scanning (0)       3.13.1.1 Confocal Scanning Laser Ophthalmoscopy (0)       3.13.1.2 Confocal Scanning Laser Polarimetry (0)     3.13.2 Optical Coherence Tomography (0)       3.13.2.1 Anterior Segment (0)       3.13.2.2 Posterior Segment (0)     3.13.3 RGC Imaging (0)     3.13.4 Other (0)   3.20 Other (0) 4 Tissue culture of ocular cells (0) 5 Experimental glaucoma; animal models (3)   5.1 Rodent (21)   5.2 Primates (2)   5.3 Other (10) 6 Clinical examination methods (0)   6.1 Intraocular pressure measurement; factors affecting IOP (1)     6.1.1 Devices, techniques (10)     6.1.2 Fluctuation, circadian rhythms (4)     6.1.3 Factors affecting IOP (20)   6.2 Tonography, aqueous flow measurement (see also 2.6) (0)   6.3 Biomicroscopy (slitlamp) (0)     6.3.1 Anterior segment (2)     6.3.2 Posterior segment (0)   6.4 Gonioscopy (4)   6.5 Ophthalmoscopy (0)   6.6 Visual field examination and other visual function tests (0)     6.6.1 Conventional manual (0)     6.6.2 Automated (20)     6.6.3 Special methods (e.g. color, contrast, SWAP etc.) (9)   6.7 Electro-ophthalmodiagnosis (5)   6.8 Photography (0)     6.8.1 Anterior segment (0)     6.8.2 Posterior segment (2)   6.9 Computerized image analysis (0)     6.9.1 Laser scanning (1)       6.9.1.1 Confocal Scanning Laser Ophthalmoscopy (13)       6.9.1.2 Confocal Scanning Laser Polarimetry (5)     6.9.2 Optical coherence tomography (1)       6.9.2.1 Anterior (5)       6.9.2.2 Posterior (12)     6.9.5 Other (1)   6.10 Fluorescein (ICG) angiography (0)     6.10.1 Anterior segment (0)     6.10.2 Posterior segment (0)   6.11 Bloodflow measurements (9)   6.12 Ultrasonography and ultrasound biomicroscopy (3)   6.13 Provocative tests (0)   6.19 Telemedicine (0)   6.20 Progression (1)   6.30 Other (0) 8 Refractive errors in relation to glaucoma (0)   8.1 Myopia (2)   8.2 Hypermetropia (0)   8.3 Contact lenses (0)   8.4 Refractive surgical procedures (0)   8.5 Other (0) 9 Clinical forms of glaucomas (0)   9.1 Developmental glaucomas (0)     9.1.1 Congenital glaucoma, Buphthalmos (10)     9.1.2 Juvenile glaucoma (11)     9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia (4)     9.1.4 Other (0)   9.2 Primary open angle glaucomas (1)     9.2.1 Ocular hypertension (1)     9.2.2 Other risk factors for glaucoma (11)     9.2.3 Open angle glaucoma with elevated IOP (4)     9.2.4 Normal pressure glaucoma (4)   9.3 Primary angle closure glaucomas (1)     9.3.1 Acute primary angle closure glaucoma (pupillary block) (6)     9.3.2 Chronic primary angle closure glaucoma (pupillary block) (4)     9.3.3 Plateau iris syndrome (0)     9.3.4 Primary angle closure suspect (1)     9.3.5 Primary angle closure (3)     9.3.10 Other (1)   9.4 Glaucomas associated with other ocular and systemic disorders (0)     9.4.1 Steroid-induced glaucoma (6)     9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera (0)       9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy) (0)       9.4.2.2 Posterior polymorphous dystrophy (0)       9.4.2.3 Fuchs' endothelial dystrophy (0)       9.4.2.5 Other (2)     9.4.3 Glaucomas associated with disorders of the iris and ciliary body (0)       9.4.3.1 Pigmentary glaucoma (1)       9.4.3.5 Other (4)     9.4.4 Glaucomas associated with disorders of the lens (0)       9.4.4.1 Exfoliation syndrome (10)       9.4.4.2 Glaucomas associated with cataracts (0)       9.4.4.3 Glaucomas associated with lens dislocation (1)       9.4.4.5 Other (0)     9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous (4)       9.4.5.1 Neovascular glaucoma (2)       9.4.5.5 Other (4)     9.4.6 Glaucomas associated with inflammation, uveitis (2)     9.4.7 Glaucomas associated with ocular trauma (2)     9.4.8 Glaucomas associated with intraocular tumors (3)     9.4.9 Glaucomas associated with elevated episcleral venous pressure (0)       9.4.10 Glaucomas associated with hemorrhage (4)     9.4.11 Glaucomas following intraocular surgery (0)       9.4.11.1 Ciliary block (malignant) glaucoma (0)       9.4.11.2 Glaucomas in aphakia and pseudophakia (13)       9.4.11.3 Epithelial, fibrous, and endothelial proliferation (0)       9.4.11.4 Glaucomas associated with corneal surgery (0)       9.4.11.5 Glaucomas associated with vitreoretinal surgery (2)     9.4.15 Glaucoma in relation to systemic disease (15)     9.4.20 Other (3) 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy (6) 11 Medical treatment (0)   11.1 General management, indication (8)   11.2 Cholinergic drugs (3)   11.3 Adrenergic drugs (0)     11.3.1 Epinephrine (0)     11.3.2 Thymoxamine, dapiprazole (0)     11.3.3 Apraclonidine, brimonidine (3)     11.3.4 Betablocker (3)     11.3.5 Other (0)   11.4 Prostaglandins (14)   11.5 Carbonic anhydrase inhibitors (1)     11.5.1 Systemic (0)     11.5.2 Topical (2)   11.6 Osmotic treatment (0)   11.7 Treatment of bloodflow (0)   11.8 Neuroprotection (15)   11.9 Gene therapy (1)   11.13 Combination therapy (1)     11.13.1 Betablocker and pilocarpine (0)     11.13.2 Betablocker and carbon anhydrase inhibitor (2)     11.13.3 Betablocker and brimonidine (1)     11.13.4 Betablocker and prostaglandin (1)     11.13.5 Other (0)   11.14 Investigational drugs; pharmacological experiments (14)   11.15 Other drugs in relation to glaucoma (4)   11.16 Vehicles, delivery systems, pharmacokinetics, formulation (8)   11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (9)   11.20 Other (2) 12 Surgical treatment (0)   12.1 General management, indication (3)   12.2 Laser iridotomy (6)   12.3 Laser iridoplasty (1)   12.4 Laser trabeculoplasty and other laser treatment of the angle (7)   12.7 Surgical iridectomy (1)   12.8 Filtering surgery (1)     12.8.1 Without tube implant (2)     12.8.2 With tube implant or other drainage devices (17)     12.8.3 Non-perforating (5)     12.8.4 Using laser (0)     12.8.5 Other (0)     12.8.10 Woundhealing antifibrosis (14)     12.8.11 Complications, endophthalmitis (5)   12.9 Trabeculotomy, goniotomy (2)   12.10 Cyclodestruction (1)   12.11 Cyclodialysis (0)   12.12 Cataract extraction (1)     12.12.1 Intracapsular (1)     12.12.2 Extracapsular (0)     12.12.3 Phacoemulsification (8)   12.14 Combined cataract extraction and glaucoma surgery (0)     12.14.1 Intracapsular (0)     12.14.2 Extracapsular (1)     12.14.3 Phacoemulsification (5)   12.15 Capsulotomy (0)   12.16 Vitrectomy (0)   12.17 Anesthesia (3)   12.20 Other (6) 13 Therapeutic prognosis and outcome (0)   13.1 Prognostic factors (4)   13.2 Outcome (0)     13.2.1 IOP (2)     13.2.2 Visual field (0)       13.2.2.1 Progression (2)       13.2.2.2 Improvement (1)     13.2.3 Other (1) 14 Costing studies; pharmacoeconomics (7) 15 Miscellaneous (9)

---

Abstract #19833 Published in IGR 9-4

Effects of ZX-5 and its optical isomers on ocular blood flow in rabbits and retinal function recovery in rats

Peng J; Zou Y-H; Jiang W; Zhang Y-H; Ji X-B; Shen Z-L; Peng S-X; Chiou GCY
International Journal of Ophthalmology 2007; 7: 1197-1201

---

AIM: The effects of ZX-5, as nitric oxide (NO) donor, on ocular blood flow has been investigated using colored microsphere technique in previous study. The relationship between the production of NO by ZX-5 and ocular blood flow has been evaluated. ZX-5 has been shown to have strong positive effect on increasing choroidal blood flow. However, the effect of ZX-5 on retinal function recovery, the effects of its optical isomers, (R, R)-ZX-5 and (S, S)-ZX-5, on choroidal blood flow and retinal function recovery have not been studied and merit investigation. METHODS: Colored microsphere technique was used for in vivo experiments to determine choroidal blood flow of ocular hypertension (40 mmHg) in rabbit eyes. Electroretinography was used to measure the b-wave recovery as an indication of retinal function recovery. RESULTS: (R, R)-ZX-5 increased choroidal blood flow at 10g/L, 50 μL instillation into eyes at all time points (P < 0.05). (S, S)-ZX-5 was not effective in increasing choroidal blood flow. ZX-5 and (R, R)-ZX-5 showed significant effects in retinal function recovery after ischemia of the retina at all time points (P < 0.05); whereas (S, S)-ZX-5 did not show significant effect on recovery of b-wave after ischemia at most time points except at 120 and 240 minutes. CONCLUSION: ZX-5 and (R, R)-ZX-5 have high potency in increasing the choroidal blood flow and improving the retinal function recovery. It is hoped that they could be used for the prevention/treatment of ocular blood flow related eye diseases.

Dr. G.C.Y. Chiou, Institute of Ocular Pharmacology and Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A and M University System Health Science Center, College Station, TX 77843, USA. chiou@medicine.tamhsc.edu

---

Classification:

6.11 Bloodflow measurements (Part of: 6 Clinical examination methods)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)

---

• ← Previous
• Next →

---